{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-034355","form_type":"8-K","ticker":"LUCD","cik":"0001799011","company_name":"Lucid Diagnostics Inc.","filed_at":"2022-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.162080+00:00","generated_at":"2026-06-21T10:21:56.917979+00:00","sec_items":["3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lucid Diagnostics issues 3.38M shares to parent PAVmed for services, expense reimbursement, and acquisition","bullets":["PAVmed elected stock for $1.65M in MSA fees (July-Sept 2022): 750,818 shares at 0.70 floor.","New PBERA formalizes expense reimbursement; PAVmed received 1,479,326 shares for $2.72M in accrued payroll/benefits.","CapNostics assignment settled with 1,145,086 shares to PAVmed, covering the ~$2.1M purchase price.","Total issuance of 3,375,230 unregistered shares to parent under Section 4(a)(2) exemptions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-034355","json":"https://secwatch.observer/filing/0001493152-22-034355.json","markdown":"https://secwatch.observer/filing/0001493152-22-034355.md","text":"https://secwatch.observer/filing/0001493152-22-034355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799011/000149315222034355/0001493152-22-034355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799011/000149315222034355/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T10:21:56.917979+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}